These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10740290)

  • 1. Elucidating cell signaling mechanisms using antisense technology.
    Koller E; Gaarde WA; Monia BP
    Trends Pharmacol Sci; 2000 Apr; 21(4):142-8. PubMed ID: 10740290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards genomic drug therapy with antisense oligonucleotides.
    Lönnberg H; Vuorio E
    Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of antisense oligonucleotides for gene functionalization and target validation.
    Bennett CF; Cowsert LM
    Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
    Golden T; Dean NM; Honkanen RE
    Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The state of the art in antisense research.
    Wagner RW
    Nat Med; 1995 Nov; 1(11):1116-8. PubMed ID: 7584973
    [No Abstract]   [Full Text] [Related]  

  • 9. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
    Branch AD
    Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of PKCalpha isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides.
    Kerkelä R; Ilves M; Pikkarainen S; Tokola H; Ronkainen J; Vuolteenaho O; Leppäluoto J; Ruskoaho H
    Mol Pharmacol; 2002 Dec; 62(6):1482-91. PubMed ID: 12435817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of Antisense Drugs.
    Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.
    Altmann KH; Fabbro D; Dean NM; Geiger T; Monia BP; Müller M; Nicklin P
    Biochem Soc Trans; 1996 Aug; 24(3):630-7. PubMed ID: 8878817
    [No Abstract]   [Full Text] [Related]  

  • 14. Antisense therapeutics: from theory to clinical practice.
    Pirollo KF; Rait A; Sleer LS; Chang EH
    Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
    Agrawal S
    Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia.
    Shiote M; Nagano I; Ilieva H; Murakami T; Narai H; Ohta Y; Nagata T; Shoji M; Abe K
    Neuroscience; 2005; 132(1):175-82. PubMed ID: 15780476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of antisense oligonucleotide inhibitors of protein expression.
    Cooper SR; Taylor JK; Miraglia LJ; Dean NM
    Pharmacol Ther; 1999; 82(2-3):427-35. PubMed ID: 10454217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligonucleotide-mediated modulation of mammalian gene expression.
    Scanlon KJ; Ohta Y; Ishida H; Kijima H; Ohkawa T; Kaminski A; Tsai J; Horng G; Kashani-Sabet M
    FASEB J; 1995 Oct; 9(13):1288-96. PubMed ID: 7557018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation.
    Sternberger M; Schmiedeknecht A; Kretschmer A; Gebhardt F; Leenders F; Czauderna F; Von Carlowitz I; Engle M; Giese K; Beigelman L; Klippel A
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):131-43. PubMed ID: 12162696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.